Induction of synergistic apoptosis by tetramethoxystilbene and nutlin-3a in human cervical cancer cells |
An, Hong-Gyu
(College of Pharmacy, Chung-Ang University)
Shin, Sangyun (College of Pharmacy, Chung-Ang University) Lee, Boyoung (College of Pharmacy, Chung-Ang University) Kwon, Yeonju (College of Pharmacy, Chung-Ang University) Kwon, Tae-Uk (College of Pharmacy, Chung-Ang University) Kwon, Yeo-Jung (College of Pharmacy, Chung-Ang University) Chun, Young-Jin (College of Pharmacy, Chung-Ang University) |
1 | Wang X, Simpson ER, Brown KA (2015) p53: protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Res 75:5001-5007. https://doi.org/10.1158/0008-5472.CAN-15-0563 DOI |
2 | Joerger AC, Fersht AR (2016) The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem 85:375-404. https://doi.org/10.1146/annurev-biochem-060815-014710 DOI |
3 | Barbarotto E, Corallini F, Rimondi E et al (2008) Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. J Cell Biochem 104:595-605. https://doi.org/10.1002/jcb.21649 DOI |
4 | Guengerich FP (2020) A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. Toxicol Res 37:1-23. https://doi.org/10.1007/s43188-020-00056-z DOI |
5 | Stanley A, Ashrafi GH, Seddon AM, Modjtahedi H (2017) Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Sci Rep 7:3964. https://doi.org/10.1038/s41598-017-04301-8 DOI |
6 | Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS (2014) Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets 15:80-89. https://doi.org/10.2174/1389450114666140106101412 DOI |
7 | Huang B, Deo D, Xia M, Vassilev LT (2009) Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol Cancer Res 7:1497-1509. https://doi.org/10.1158/1541-7786.MCR-09-0144 DOI |
8 | Susin SA, Lorenzo HK, Zamzami N et al (1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397:441-446. https://doi.org/10.1038/17135 DOI |
9 | Lipton SA, Bossy-Wetzel E (2002) Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 111:147-150. https://doi.org/10.1016/s0092-8674(02)01046-2 DOI |
10 | Daugas E, Susin SA, Zamzami N et al (2000) Mitochondrionuclear translocation of AIF in apoptosis and necrosis. FASEB J 14:729-739. https://doi.org/10.1096/fasebj.14.5.729 DOI |
11 | Loeffler M, Daugas E, Susin SA et al (2001) Dominant cell death induction by extramitochondrially targeted apoptosisinducing factor. FASEB J 15:758-767. https://doi.org/10.1096/fj.00-0388com DOI |
12 | Mondesire WH, Jian W, Zhang H et al (2004) Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10:7031-7042. https://doi.org/10.1158/1078-0432.CCR-04-0361 DOI |
13 | DeVita VT Jr, Young RC, Canellos GP (1975) Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35:98-110. https://doi.org/10.1002/1097-0142(197501)35:198::aidcncr28203501153.0.co;2-b DOI |
14 | Fan C, Zheng W, Fu X, Li X, Wong YS, Chen T (2014) Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis 5:e1191. https://doi.org/10.1038/cddis.2014.132 DOI |
15 | Kojima K, Konopleva M, Samudio IJ et al (2005) MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106:3150-3159. https://doi.org/10.1182/blood-2005-02-0553 DOI |
16 | Deben C, Wouters A, Op de Beeck K et al (2015) The MDM2-inhibitor nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. Oncotarget 6:22666-22679. https://doi.org/10.1158/1541-7786.MCR-09-0144 DOI |
17 | Carter BZ, Mak DH, Schober WD et al (2010) Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 115:306-314. https://doi.org/10.1182/blood-2009-03-212563 DOI |
18 | Kwon YJ, Baek HS, Ye DJ, Shin S, Kim D, Chun YJ (2016) CYP1B1 enhances cell proliferation and metastasis through induction of EMT and activation of Wnt/β-catenin signaling via sp1 upregulation. PLoS One 11:e0151598. https://doi.org/10.1371/journal.pone.0151598 DOI |
19 | Baek HS, Kwon YJ, Ye DJ, Cho E, Kwon TU, Chun YJ (2019) CYP1B1 prevents proteasome-mediated XIAP degradation by inducing PKCε activation and phosphorylation of XIAP. Biochim Biophys Acta Mol Cell Res 1866:118553. https://doi.org/10.1016/j.bbamcr.2019.118553 DOI |
20 | Park HS, Aiyar SE, Fan P et al (2007) Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. Cancer Res 67:5717-5726. https://doi.org/10.1158/0008-5472.CAN-07-0056 DOI |
21 | Yan C, Huang D, Zhang Y (2011) The involvement of ROS overproduction and mitochondrial dysfunction in PBDE-47-induced apoptosis on Jurkat cells. Exp Toxicol Pathol 63:413-417. https://doi.org/10.1016/j.etp.2010.02.018 DOI |
22 | Yu SW, Andrabi SA, Wang H et al (2006) Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 103:18314-18319. https://doi.org/10.1073/pnas.0606528103 DOI |
23 | Kuganesan N, Dlamini S, Tillekeratne LMV, Taylor WR (2021) Tumor suppressor p53 promotes ferroptosis in oxidative stress conditions independent of modulation of ferroptosis by p21, CDKs, RB, and E2F. J Biol Chem 297:101365. https://doi.org/10.1016/j.jbc.2021.101365 DOI |
24 | Delavallee L, Mathiah N, Cabon L et al (2020) Mitochondrial AIF loss causes metabolic reprogramming, caspase-independent cell death blockade, embryonic lethality, and perinatal hydrocephalus. Mol Metab 40:101027. https://doi.org/10.1016/j.molmet.2020.101027 DOI |
25 | Kwon YJ, Shin S, Chun YJ (2021) Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes. Arch Pharm Res 44:63-83. https://doi.org/10.1007/s12272-021-01306-w DOI |
26 | Tallarida RJ (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298:865-872. https://jpet.aspetjournals.org/content/298/3/865.long |
27 | Schimmer AD, Dalili S, Batey RA, Riedl SJ (2006) Targeting XIAP for the treatment of malignancy. Cell Death Differ 13:179-188. https://doi.org/10.1038/sj.cdd.4401826 DOI |
28 | Murray GI (2000) The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol 192:419-426. https://doi.org/10.1002/1096-9896(2000)9999:9999::AID-PATH7503.0.CO;2-0 DOI |
29 | Chun YJ, Kim S, Kim D, Lee SK, Guengerich FP (2001) A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res 61:8164-8170. https://aacrjournals.org/cancerres/article/61/22/8164/508230/ANew-Selective-and-Potent-Inhibitor-of-Human |
30 | Kim SW, Jung HK, Kim MY (2008) Induction of p27kip1 by 2,4,3',5'-tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. Arch Pharm Res 31:1187-1194. https://doi.org/10.1007/s12272-001-1287-1 DOI |
31 | Cosentino K, Garcia-Saez AJ (2017) Bax and bak pores: are we closing the circle. Trends Cell Biol 27:266-275. https://doi.org/10.1016/j.tcb.2016.11.004 DOI |
32 | Kuwana T, Mackey MR, Perkins G et al (2002) Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111:331-342. https://doi.org/10.1016/s0092-8674(02)01036-x DOI |
33 | Schimmer AD (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64:7183-7190. https://doi.org/10.1158/0008-5472.CAN-04-1918 DOI |
34 | Kocik J, Machula M, Wisniewska A, Surmiak E, Holak TA, Skalniak L (2019) Helping the released guardian: drug combinations for supporting the anticancer activity of HDM2 (MDM2) antagonists. Cancers (Basel) 11:1014. https://doi.org/10.3390/cancers11071014 DOI |
35 | Davis JR, Mossalam M, Lim CS (2013) Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2. Mol Pharm 10:1340-1349. https://doi.org/10.1021/mp300543t DOI |
36 | Khoo KH, Verma CS, Lane DP (2014) Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 13:217-236. https://doi.org/10.1038/nrd4236 DOI |
37 | Nakamura M, Obata T, Daikoku T, Fujiwara H (2019) The association and significance of p53 in gynecologic cancers: the potential of targeted therapy. Int J Mol Sci 20:5482. https://doi.org/10.3390/ijms20215482 DOI |
38 | Tsao CC, Corn PG (2010) MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines. Cancer Biol Ther 10:1315-1325. https://doi.org/10.4161/cbt.10.12.13612 DOI |
39 | Tonsing-Carter E, Bailey BJ, Saadatzadeh MR et al (2015) Potentiation of carboplatin-mediated DNA damage by the mdm2 modulator nutlin-3a in a humanized orthotopic breast-to-lung metastatic model. Mol Cancer Ther 14:2850-2863. https://doi.org/10.1158/1535-7163.MCT-15-0237 DOI |
40 | Turner N, Moretti E, Siclari O et al (2013) Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev 39:541-550. https://doi.org/10.1016/j.ctrv.2012.12.001 DOI |
41 | Chun YJ, Lee SK, Kim MY (2005) Modulation of human cytochrome P450 1B1 expression by 2,4,3',5'-tetramethoxystilbene. Drug Metab Dispos 33:1771-1776. https://doi.org/10.1124/dmd.105.006502 DOI |
42 | Yu SW, Wang H, Poitras MF et al (2002) Mediation of poly (ADP-ribose) polymerase-1-dependent cell death by apoptosisinducing factor. Science 297:259-263. https://doi.org/10.1126/science.1072221 DOI |
43 | Shi Y (2004) Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci 13:1979-1987. https://doi.org/10.1110/ps.04789804 DOI |
44 | Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209-249. https://doi.org/10.3322/caac.21660 DOI |
45 | Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N (2017) Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:72-83. https://doi.org/10.1093/annonc/mdx220 DOI |
46 | Wrzesien-Kus A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T (2004) The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis 9:705-715. https://doi.org/10.1023/B:APPT.0000045788.61012.b2 DOI |
47 | Tovar C, Rosinski J, Filipovic Z et al (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103:1888-1893. https://doi.org/10.1073/pnas.0507493103 DOI |
48 | Ohnstad HO, Paulsen EB, Noordhuis P et al (2011) MDM2 antagonist nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer 11:211:1-11. https://doi.org/10.1186/1471-2407-11-211 DOI |
49 | Kwon YJ, Cho NH, Ye DJ, Baek HS, Ryu YS, Chun YJ (2018) Cytochrome P450 1B1 promotes cancer cell survival via specificity protein 1 (Sp1)-mediated suppression of death receptor 4. J Toxicol Environ Health A 81:278-287. https://doi.org/10.1080/15287394.2018.1440186 DOI |
50 | Hong M, Park N, Chun YJ (2014) Role of annexin a5 on mitochondria-dependent apoptosis induced by tetramethoxystilbene in human breast cancer cells. Biomol Ther (Seoul) 22:519-524. https://doi.org/10.4062/biomolther.2014.112 DOI |
51 | Urbano A, Lakshmanan U, Choo PH et al (2005) AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cells. EMBO J 24:2815-2826. https://doi.org/10.1038/sj.emboj.7600746 DOI |
52 | Palenski TL, Sorenson CM, Jefcoate CR, Sheibani N (2013) Lack of Cyp1b1 promotes the proliferative and migratory phenotype of perivascular supporting cells. Lab Invest 93:646-662. https://doi.org/10.1038/labinvest.2013.55 DOI |